| Balance sheet (USD) | Q2 2025 ended Jun 30, 2025 | Q2 2025 ended Mar 31, 2025 | Q2 2024 ended Jun 30, 2024 | Q2 2024 ended Mar 31, 2024 | Q2 2023 ended Jun 30, 2023 | Q1 2023 ended Mar 31, 2023 | Q4 2022 ended Dec 31, 2022 | Q3 2022 ended Sep 30, 2022 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.45M | 5.04M | 10.38M | 20.77M | 13.52M | 10.74M | ||
| Total current assets | 10.61M | 13.46M | 27.70M | 33.78M | 41.74M | 48.73M | ||
| Property, plant and equipment | 217.0K | 276.0K | 338.0K | 352.0K | 367.0K | 380.0K | ||
| Total assets | 11.13M | 14.54M | 28.85M | 35.01M | 43.06M | 50.22M | ||
| Total current liabilities | 1.43M | 4.31M | 6.83M | 7.00M | 6.75M | 5.48M | ||
| Total liabilities | 1.43M | 4.56M | 6.86M | 7.06M | 6.84M | 5.59M | ||
| Retained earnings | -108.00M | -96.18M | -80.54M | -72.57M | -63.82M | -55.55M | ||
| Shareholders' equity | 9.70M | 10.39M | 9.98M | 13.33M | 21.99M | 27.95M | 36.22M | 44.62M |
From Chemomab Therapeutics Ltd.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.